E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Selected Advanced Solid Tumors. |
|
E.1.1.1 | Medical condition in easily understood language |
Selected Advanced Solid Tumors. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048683 |
E.1.2 | Term | Advanced cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the antitumor activity of lurbinectedin (PM01183) in terms of overall response rate (ORR), according to RECIST v 1.1 in the following advanced solid tumors: small cell lung cancer (SCLC), head and neck carcinoma (H&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs) and Ewing´s family of tumors (EFTs). |
|
E.2.2 | Secondary objectives of the trial |
*Characterize the antitumor activity of PM01183 in terms of duration of response (DR), clinical benefit (ORR or stable disease (SD) lasting over four months (SD>=4 months)), progression-free survival (PFS) and one-year overall survival (1y-OS) in each cohort of advanced solid tumors.
*Characterize the plasma pharmacokinetics (PK) of PM01183.
*Conduct an exploratory pharmacogenomic (PGx) and pharmacogenetic analysis.
*Evaluate the safety profile of PM01183 in this patient population. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
An exploratory pharmacogenomic (PGx) and pharmacogenetic sub-study. |
|
E.3 | Principal inclusion criteria |
1)Age >/= 18 years.
2)Voluntary signed informed consent (IC) of the patient before any study-specific procedure.
3)Pathologically proven diagnosis of any of the following malignancies:
a)Small cell lung cancer (SCLC).
b)Head and neck carcinoma (H&N). Salivary glands tumors are excluded.
c)Neuroendocrine tumors (NETs),grade 2 and 3 according to World Health Organization (WHO) classification.
d)Biliary tract carcinoma.
e)Endometrial carcinoma.
f)Carcinoma of unknown primary site.
g)Germ cell tumor (GCTs), excluding immature teratoma, or teratoma with malignant transformation.
h)Ewing's family of tumors (EFTs).
4)Prior treatment. Patients must have received:
a)SCLC: one prior chemotherapy-containing line.
b)H&N: one or two prior chemotherapy-containing lines.
c)NETs: one or two prior chemotherapy-containing lines. No more than three prior hormone or biological therapy lines.
d)Biliary tract carcinoma: one or two prior chemotherapy-containing lines.
e)Endometrial carcinoma: one prior chemotherapy-containing line.
f)Carcinoma of unknown primary site: one or two prior chemotherapy-containing lines.
g)GCTs: no limit of prior therapy (patients with no other clinical therapeutic options).
h)EFTs: no more than two prior chemotherapy-containing lines in the
metastatic/recurrent setting.
5)Measurable disease as defined by RECIST v.1.1, and documented progression before study entry.
6)Eastern Cooperative Oncology Group (ECOG) performance status (PS) </= 2.
7)Adequate major organ function:
a)Hemoglobin >/= 9 g/dl, prior red blood cell (RBC) transfusions are allowed if clinically indicated; absolute neutrophil count (ANC) >/= 2.0 x 109/l; and platelet count >/= 100 x 109/l.
b)Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) </= 3.0 x upper limit of normal (ULN).
c)Total bilirubin </= 1.5 x ULN, or direct bilirubin
</= ULN.
d)Albumin >/= 3 g/dl.
e)Serum creatinine </= 1.5 x ULN or creatinine clearance >/= 30 ml/min.
f)Creatine phosphokinase (CPK) </= 2.5 x ULN.
8)Washout periods prior to Day 1 of Cycle 1:
a)At least three weeks since the last chemotherapy (six weeks if therapy contained nitrosureas or systemic mitomycin C).
b)At least four weeks since the last monoclonal antibody (MAb)-containing therapy, or radiotherapy (RT) > 30 gray (Gy).
c)At least two weeks since the last biological/investigational therapy (excluding MAbs) or palliative RT (</= 10 fractions or </= 30 Gy total dose).
9)Grade </= 1 toxicity due to any previous cancer therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.4). Grade 2 is allowed in case of alopecia and/or peripheral sensory neuropathy.
10)Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry. Fertile women must agree to use a medically acceptable method of contraception throughout the treatment period and for at least three months after treatment discontinuation. Fertile men must agree to refrain from fathering a child or donating sperm during the trial and for four months after the last infusion. |
|
E.4 | Principal exclusion criteria |
1)Prior treatment with PM01183 or trabectedin.
2)Prior or concurrent malignant disease unless in complete remission for more than five years, except treated in situ carcinoma of the cervix, basal or squamous cell skin carcinoma, and in situ transitional cell bladder carcinoma.
3)Known central nervous system (CNS) involvement. In patients with SCLC, brain computed tomography (CT)-scan or magnetic resonance imaging(MRI) results must be provided at baseline.
4)Relevant diseases or clinical situations which may increase the patient´s risk:
a)History within the last year or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically relevant valvular heart disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia requiring ongoing treatment.
b)Grade >/= 3 dyspnea or daily intermittent oxygen requirement within two weeks prior to the study treatment onset.
c)Active infection.
d)Unhealed wounds or presence of any external drainage.
e)Known chronic active hepatitis or cirrhosis.
f)Immunocompromised patients, including known infection by human immunodeficiency virus (HIV).
5)Women who are pregnant or breast-feeding, and fertile
patients (men and women) who are not using an effective
method of contraception. *
6)Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression).
7)Limitation of the patient?s ability to comply with the treatment or to follow-up the protocol.
* Women of childbearing potential (WOCBP) must agree to
use an effective contraception method to avoid pregnancy
during the course of the trial (and for at least three months after
the last infusion). Valid methods to determine the childbearing
potential, adequate contraception and requirements for WOCBP
partners are described in APPENDIX 2. Fertile male patients
must agree to refrain from fathering a child or donating sperm
during the trial and for four months after the last infusion. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Response Rate (ORR) in each tumor type. ORR is defined as the percentage of patients with a confirmed response, either complete (CR) or partial (PR), according to the RECIST (v. 1.1). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Efficacy: Duration of Response (DR), defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when PD, recurrence or death is documented. Clinical Benefit, defined as ORR or stable disease lasting over four months (SD >/= 4 months). Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation. PFS4/PFS6, defined as the Kaplan-Meier estimates of the probability of being free from progression and death after the first infusion at these time points (4 and 6 months). OS6/OS12,
defined as the Kaplan-Meier estimates of the probability of being alive after the first infusion at these time points (6 and 12 months). Plasma Pharmacokinetics (PK) of PM01183 Non-compartmental (NCA) PK parameters: area under the curve (AUC), maximum plasma concentration (Cmax), clearance (CL) and half-life (t1/2).
Population PK parameters of the compartment model to be developed (initially based on Volumes and Clearance), and PK/PD correlation parameters, if applicable. Pharmacogenetics This analysis will be performed in those patients who signed the IC for the pharmacogenetic sub-study. The presence or absence of
known polymorphisms from a single sample collected just before the PM01183 treatment start will be assessed to explain the individual variability in the main PK parameters. Pharmacogenomics (PGx): This exploratory analysis will be performed in those patients treated in any arm who signed the IC for the PGx sub-study. mRNA or protein expression levels of factors involved in DNA repair mechanisms, or related to the mechanism of action of lurbinectedin, will be evaluated from prior available tumor tissue samples obtained at diagnosis or relapse. Their mutational status might be also analyzed. Their correlation with the clinical response and outcome after treatment will be assessed. Safety Profile: Clinical examinations. Clinical assessment of AEs and serious adverse events (SAEs). Changes in laboratory parameters (hematological and biochemical, including liver function tests). Reasons for treatment discontinuations. Reasons for dose reduction and treatment delays. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 21 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When all evaluable patients have at least 12 months of follow-up. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |